Quarterly report pursuant to Section 13 or 15(d)

Other Income / (Expense) (Tables)

v3.22.2.2
Other Income / (Expense) (Tables)
3 Months Ended
Sep. 30, 2022
Notes Tables  
Schedule of the components of other income (expense)

Quarter Ended

September 30, 

    

2022

    

2021

Interest expense

$

(3,790)

$

(3,409)

Interest income

433

193

Other non-operating income (expense), net(1)

 

50,756

 

7,377

Total other income (expense)

$

47,399

$

4,161

(1)

Primarily due to a $37.2 million gain on the sale of our ChemoCentryx investment and a $11.7 million gain on the sale of Eminence.